Commercial Trading Update

Aptamer Group PLC

06 November 2024

 

6 November 2024

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Commercial Trading Update

Aptamer Group plc (AIM: APTA), the developer of novel Optimer^® binders to enable innovation in the life sciences industry, is pleased to provide an update on contracts signed since its financial year ended 30 June 2024.

Aptamer has secured new contracts worth up to £471,000 continuing the positive commercial traction achieved during the last quarter of the previous financial year. These contracts include multiple agreements, including two from top 20 and one from a top 5 global pharmaceutical companies, totalling up to £340,000. These projects are aimed at developing Optimers as critical reagents to support active clinical development programmes and facilitate the analysis of novel therapeutics.

A significant proportion of these deals involve repeat customers who are advancing Aptamer's binders within their internal pipelines, with some signalling intent for long-term licensing revenues. This ongoing traction highlights Aptamer's role in supporting key industry players and reinforces our position as a key player in the market.

These new contracts illustrate Aptamer's increasing commercial traction and the Group's ability to secure repeat business from top pharmaceutical companies. Aptamer now has booked revenue contracts of up to c. £1.2m to recognise throughout FY25 (Jun 25 year-end) and an increased sales pipeline from £2.1m in July 2024 to £4.0m as of today.

Dr Arron Tolley, Chief Executive Officer of Aptamer Group said: "Following the fundraise in August 2024, I am pleased to report that the sustained focus of our commercial team continues to bear fruit. We are advancing steadily towards our revenue and potential licensing goals for FY 25 with the best part of 7 months left in the financial year. Revenue generation and increased income from licensing form a pivotal component of the Group's strategy to deliver shareholder value and I look forward to updating you on future contracts and key project updates."  

- Ends -

For further information, please contact: 

Aptamer Group plc   Arron Tolley, Chief Executive Officer	[phone]
SPARK Advisory Partners Limited - Nominated Adviser     Andrew Emmott / Adam Dawes	[phone]
Turner Pope Investments (TPI) Limited - Broker     James Pope / Andrew Thacker	[phone]
Northstar Communications Limited - Investor Relations Sarah Hollins	[phone]

About Aptamer Group plc 

Aptamer Group develops custom affinity binders through its proprietary Optimer^® platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers. 

Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over $170 billion.  

Aptamer has successfully delivered projects for a range of global pharma companies, diagnostic development companies, and research institutes, covering multiple application areas with the objective of establishing royalty-bearing licenses.  

 

END